Niagen Bioscience(NASDAQ) NAGE

Niagen Bioscience, Inc. makes products to help people age healthily. It sells supplements that boost levels of an essential cellular coenzyme. These products help support how cells work in the body.

What Does Niagen Sell?

• Consumer Products: Finished supplements and skincare products like Tru Niagen sold to consumers and distributors; generated $24.2 million in net sales for the three-month period ended June 30, 2026.
• Ingredients: Proprietary technologies sold to manufacturers and pharmacies for various health applications; generated $5.4 million in net sales for the three-month period ended June 30, 2026.
• Pharmaceutical Development: Research on molecules for rare genetic diseases and aging-related disorders; currently generates zero revenue.

Strategic Moves and New Science

• Sold the analytical reference standards and services segment in Feb. 2026 for $6.0 million to focus on core products.
• Introduced NB4168 in July 2026 as a lead investigational drug candidate for the treatment of a rare genetic disease called Ataxia-Telangiectasia.
• Launched a clinician-directed telehealth platform in May 2026 to allow patients to access prescription-based products.
• Reached an agreement with a retail partner in Asia in April 2026 to resolve a previously disclosed product recall dispute.

Research and Intellectual Property

The company manages a research program with universities to study nicotinamide adenine dinucleotide, which is a molecule vital for cellular metabolism. It maintains a portfolio of owned and licensed patents to protect its proprietary ingredients and pharmaceutical candidates.

Important Facts and Figures

• Net sales reached $29.8 million for the three-month period ended June 30, 2026, down 4% year over year.
• Market capitalization was $352.4 million in Q1 2026, down 34.4% year over year.
• Net income reached $7.3 million for the six-month period ended June 30, 2026.
• Cash and cash equivalents totaled $66.7 million as of June 30, 2026.
• Marketing expenses for the consumer products segment rose to 41.0% of net sales in the three-month period ended June 30, 2026.

Bottom Line

Niagen Bioscience has moved from a multi-segment research firm to a focused developer of consumer health and pharmaceutical products. Its exit from noncore services and expansion into telehealth platforms supports its strategy to scale its proprietary aging technologies.